This Cannabis Stock Can Still Make You Rich

HEXO (TSX:HEXO)(NYSE:HEXO) used to be a $2 billion cannabis stock. Now valued at just $400 million, it’s time for growth investors to take another look.

| More on:
edit Jars of marijuana

Image source: Getty Images

Cannabis was a quick way to get rich. During the 2018 boom, pot stocks soared in value. A $1,000 investment could grow to $5,000 in a matter of weeks.

Everything changed in 2019. That year, marijuana producers collapsed in value. The industry lost billions of dollars in value.

Today, valuations are still at rock bottom. If you want to get rich, this is exactly the situation you should look for. As Warren Buffett advises, you want to be greedy when others are fearful. And right now, cannabis investors are the definition of fearful.

This is your chance to profit.

This strategy works

There are dozens of cannabis stocks to choose from, nearly all of which trade at multi-year lows. If there’s another bull market, most of these businesses will rise in value. But how do you identify the ones that can rise 10 times in value or more?

There’s one simple filter that you should apply to every candidate: can the firm avoid commoditization?

When the cannabis boom began in 2018, investors rushed into any related stock. Few scrutinized the business models closely. If the firm dealt with pot, shares skyrocketed.

This dynamic was similar to the dot-com boom in the late 90s. As long as a company did something related to the internet, the market sent the shares higher.

When a bubble bursts, scrutiny soars. That’s what happened following the dot-com bubble, and it’s happening again with the cannabis industry. Investors are jaded. They’re unwilling to make bets on the future by pricing in potential growth. This is why such a giant opportunity exists.

Which cannabis stocks will soar when the market takes off next? Firms that build brands that consumers love. That’s the only way to avoid the impact of commoditization.

The best cannabis stock

If I sold water and sugar on the open market, no one would pay me a premium. I’ll fetch whatever the market price is. But if those ingredients are combined into a branded product like Coca-Cola, consumers will pay a big premium.

Cannabis companies that replicate this strategy will win. So far, HEXO (TSX:HEXO)(NYSE:HEXO) has a big lead.

From the start, HEXO played the game differently. Instead of ramping marijuana production as fast as possible, the firm focused on building partnerships with existing brands. HEXO’s CEO knew long ago that great branding would result in sales growth and industry-leading margins.

Results came in quickly. Last year, HEXO partnered with Molson Coors to co-produce cannabis-infused drinks in Canada. In 2020, the partnership was expanded to include the lucrative U.S. market.

Molson clearly likes what it sees from HEXO. That’s useful social validation.

When these products arrive, they should quickly take market share. How could an upstart competitor compete with a Molson-branded product? Millions of consumers in North America already know and love the brand.

Right now, HEXO trades at a $400 million market cap. Once its new products launch, expect the firm to regain its $1 billion valuation. With the best strategy in the industry, long-term growth should add even more value.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool recommends HEXO. and HEXO. Fool contributor Ryan Vanzo has no position in any stocks mentioned.

More on Coronavirus

rail train
Coronavirus

Bull or Bear: Why Analysts Changed Their Tune on Aecon Stock

Analysts had been champing at the bit for the construction company, but the tides have turned.

Read more »

Biotech stocks
Coronavirus

Is Bellus Health Stock Still a Buy After 30% Earnings Jump?

The biotech continues to make progress on obtaining FDA approval for its chronic-cough therapy.

Read more »

grow dividends
Coronavirus

Goodfood Stock Likely to Double in 2022!

Goodfood (TSX:FOOD) stock has had a huge rise and fall in the last few years. But at $1.85 a share,…

Read more »

grow dividends
Coronavirus

Canfor Stock Pops 5% as Sales Climb 15% YOY

Canfor (TSX:CFP) stock remained positive about its future in the global lumber market after profits climb 15% year over year.

Read more »

edit Safety First illustration
Coronavirus

2 Crash-Proof TSX Stocks I’d Buy With $5,000

These two TSX stocks have proven they can handle this economic downturn and likely will continue to be safe far…

Read more »

TSX Today
Coronavirus

What to Watch on the TSX on Tuesday, April 26

Earnings continue to come out on the TSX today, including Air Canada (TSX:AC). Meanwhile, investors may want to continue watching…

Read more »

think thought consider
Coronavirus

Should Investors Buy Goodfood Stock Ahead of Earnings?

Goodfood (TSX:FOOD) stock dropped on Wednesday ahead of the company's earnings release. And it's unclear whether there will be anything…

Read more »

little girl in pilot costume playing and dreaming of flying over the sky
Coronavirus

Cargojet Stock Soars Higher, Is it Still a Buy?

Cargojet stock (TSX:CJT) jumped after its deal with DHL, but at today's prices is the airline company still a buy…

Read more »